Skip to main content
. Author manuscript; available in PMC: 2010 Jan 4.
Published in final edited form as: Coron Artery Dis. 2009 May;20(3):207–213. doi: 10.1097/MCA.0b013e328329924b

Figure 1. Clopidogrel 150 mg/day significantly decreased ADP-induced platelet function as assessed by the VerifyNow assay.

Figure 1

Subjects with known CAD collectively demonstrated decreased platelet aggregation with 150 mg of clopidogrel at 30 days compared with 75 mg of clopidogrel at baseline and 60 days (p = 0.013). Although extensive variability was present, overall there was no significant difference in platelet response at 60 days compared to baseline. Platelet function was assessed by the VerifyNow point of care device, and values are reported as P2Y12 reaction units (PRU). In the top portion of the figure, individual subject values are plotted across the 3 time points from baseline (75 mg) to 30 days (150 mg) to 60 days (75 mg). Solid lines indicate subjects whose values decreased from baseline to the 30-day time point, and dashed lines denote an increase from baseline to 30 days. In the bottom portion of the figure, aggregate results (mean ± standard deviation) are presented for each time point.